Characteristics of the study population by quartiles of total adiponectin*
| Quartile (n) | Total | Q1 (798) | Q2 (797) | Q3 (798) | Q4 (797) |
|---|---|---|---|---|---|
| Adiponectin (mg/L) | 0.8–55 | ≤8.7 | >8.7–12.4 | 12.4–17.6 | >17.6 |
| Age, years | 74±5 | 73±5 | 74±5 | 74±5 | 76±6 |
| Men, n (%) | 1159 (36.3) | 463 (58.0) | 329 (41.3) | 231 (28.9) | 136 (17.1) |
| African-American, n (%) | 524 (16.4) | 234 (29.3) | 142 (17.8) | 87 (10.9) | 61 (7.7) |
| Education<high school, n (%) | 807 (25.3) | 235 (29.4) | 209 (26.2) | 177 (22.2) | 186 (23.3) |
| BMI, kg/m2 | 26.8±4.8 | 28.6±4.7 | 27.6±4.4 | 26.5±4.7 | 24.6±4.2 |
| Height, cm | 164±9 | 167±9 | 165±9 | 163±9 | 160±8 |
| Weight, kg | 159±32 | 80.2±13.9 | 75.0±13.4 | 70.3±13.4 | 63.0±12.2 |
| Systolic blood pressure, mm Hg | 136±21 | 136±21 | 136±21 | 136±21 | 135±20 |
| Diastolic blood pressure, mm Hg | 72±11 | 73±11 | 73±11 | 71±11 | 71±11 |
| Hypertensive medication, n (%) | 1277 (40.0) | 360 (45.1) | 361 (45.3) | 296 (37.1) | 260 (32.6) |
| Diabetes, n (%) | 385 (12.3) | 211 (26.9) | 78 (9.9) | 65 (8.3) | 31 (4.0) |
| HOMA-IR | 3.7±7.3 | 6.3±11.6 | 3.6±6.1 | 2.9±5.2 | 2.2±2.5 |
| LDL, mg/dL | 128±33 | 126±34 | 129±34 | 129±33 | 126±34 |
| HDL, mg/dL | 55±14 | 47±11 | 51±12 | 57±12 | 65±15 |
| Triglyceride, mg/dL | 121 (87, 168) | 145 (106, 208) | 129 (95, 179) | 116 (86, 154) | 99 (74, 133) |
| Lipid medication, n (%) | 198 (6.2) | 55 (6.9) | 62 (7.8) | 46 (5.8) | 35 (4.4) |
| Current smoker, n (%) | 334 (10.5) | 93 (11.7) | 81 (10.2) | 87 (10.9) | 73 (9.2) |
| Alcohol use ≥7 drinks/week | 421 (13.2) | 92 (11.5) | 94 (11.8) | 113 (14.2) | 122 (15.3) |
| Oestrogen replacement (women) | 293 (9.2) | 32 (4.0) | 74 (9.3) | 87 (10.9) | 100 (12.5) |
| ACE inhibitor medication | 267 (8.4) | 91 (11.4) | 68 (8.5) | 62 (7.8) | 46 (5.8) |
| Beta-blocker medication | 265 (8.3) | 93 (11.7) | 86 (10.8) | 47 (5.9) | 39 (4.9) |
| Self-reported fair/poor health | 479 (15.0) | 133 (16.7) | 111 (13.9) | 109 (13.7) | 126 (15.8) |
| Unintentional wt loss >10 lbs | 136 (4.7) | 33 (4.5) | 26 (3.6) | 32 (4.4%) | 45 (6.3) |
| eGFR, mL/min/m1.73 | 75±18 | 75±19 | 75±18 | 75±17 | 76±19 |
| hsCRP, mg/L | 2.4 (1.1, 5.5) | 3.7 (1.8, 6.7) | 2.8 (1.2, 5.9) | 2.1 (1.0, 5.1) | 1.6 (0.8, 3.3) |
| NT-proBNP1–76, ng/L | 114 (61, 212) | 72 (40, 137) | 101 (59, 177) | 130 (74, 224) | 170 (98, 289) |
| Subclinical CVD, n (%) | 1958 (63.0) | 529 (67.9) | 487 (62.7) | 482 (62.0) | 460 (59.5) |
| High LA diameter index†, n (%) | 177 (6.8) | 35 (5.2) | 36 (5.5) | 40 (6.0) | 66 (10.7) |
| Low LVEF (<55%)†, n (%) | 150 (5.9) | 42 (6.5) | 35 (5.6) | 38 (5.9) | 35 (5.7) |
| Transmitral E/A ratio†, n (%) | |||||
| <0.7 | 611 (23.7) | 159 (23.7) | 173 (26.7) | 152 (23.3) | 127 (20.8) |
| 0.7–1.5 | 1908 (73.9) | 501 (74.8) | 454 (70.1) | 488 (74.7) | 465 (76.2) |
| >1.5 | 62 (2.4) | 10 (1.5) | 21 (3.2) | 13 (2.0) | 18 (3.0) |
| Incident AF, n (%) | 886 (27.8) | 211 (26.4) | 219 (27.5) | 239 (29.9) | 217 (27.2) |
| Incident HF before AF, n (%) | 619 (19.4) | 163 (20.4) | 163 (20.5) | 152 (19.0) | 141 (17.7) |
| Incident CHD before AF | 822 (25.8) | 240 (30.1) | 222 (27.9) | 193 (24.2) | 167 (21.0) |
*Continuous values are presented as means±SD or as medians (IQR).
†Obtained 2 years after the 1992–1993 baseline (ie, at the 1994–1995 examination)
AF, atrial fibrillation; BMI, body mass index; CHD, coronary heart disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HF, heart failure; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment-insulin resistance; hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; LA, left atrial; NT-proBNP1–76, amino-terminal pro-B-type natriuretic peptide 1–76; wt, weight.